Chris Bunge
Hedge fund analyst, long/short equity

Alcobra: The Next Big Thing In ADHD

On December 16, 2013 Alcobra announced its lead drug compound MG01C1 had TOVA and CAARS Scores equal to if not better than all existing players (this is how the industry measures efficacy in ADHD). Based upon their involuntary read out, I believe the stock is highly undervalued. Since December 20th, the stock has risen 20%; however, as I dig deeper within the December 16th report, it appears to be a major inflection point within their business. Dr. Yaron Daniely (the CEO of Alcobra) has publicly stated that their corporate strategy pending positive phase III results is to sell the company.

Business Description:

ADHD is one of the most common behavioral disorders in the world. Alcobra has stated that the market...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details